Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vitamin D in IBD
NCT04828031Phase 1Completed
- Sponsor
- Stanford University
- Start
- Jul 2021
- Primary completion
- Jul 2023
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vitamin d in inflammatory bowel disease (IBD), sponsored by Stanford University. Primary endpoints: Reduction in α4β7+ B cells by 20% at 12 weeks and Reduction in immunoglobulin coating of commensal gut bacteria by 20% at 12 weeks. Started Jul 2021; status: completed.
02
Drugs
vitamin d
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT04828031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04828031.